Onilcamotide

DETAILS

Cas: 1164096-85-8
Purity: 98%
Smiles: CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O
Category: Compound
Molecular Weight: 2293.78
Molecular Formula: C96H177N39O24S

DESCRIPTION

Onilcamotide, a cancer vaccine derived from the C-terminal peptide of the RhoC protein, exhibits potential immunomodulating and antineoplastic activities.

Lead Time: 4 - 5 weeks